TB 500 (Thymosin Beta-4) is a peptide involved in: Cell migration and division Actin regulation Blood vessel formation Muscle and connective tissue repair TB 500 is commonly researched for improving mobility, flexibility, and recovery in musculoskeletal models
The following adverse effects were reported in patients receiving semaglutide injection or oral tablets across all clinical trials and at incidences higher than with placebo: nausea (11% to 44%), vomiting (5% to 24%), diarrhea (8.5% to 30%), abdominal pain (5.7% to 20%), abdominal distention (2% to 7%), constipation (3.1% to 24%), dyspepsia (0.6% to 9%), decreased appetite (6% to 9%), eructation (0.6% to 7%), flatulence (0.4% to 6%), gastroesophageal reflux disease (1.5% to 5%), gastroenteritis (4% to 6%), and gastritis (0.4% to 4%)
Measurable weight loss typically begins within 2 to 4 weeks
Retatrutide is not approved by Health Canada for clinical or human use
NAC and glutathione supplementation both help to boost antioxidant capacity